

Application Number 10/574048
Response to Office Action dated 12/10/2007


RECEIVED
CENTRAL FAX CENTER
FEB 28 2008

Amendments to the Claims:


This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1. (Original) A compound represented by Formula (I):



wherein R is a cyclic hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; X is a bond or a divalent chain hydrocarbon group which may be substituted; X' is a bond or $-N(R^5)-$ (wherein R^5 is a hydrogen atom, a hydrocarbon group which may be substituted, an esterified or amidated carboxyl group, or an acyl group); Y is a divalent hydrocarbon group which may be substituted; Y' is a bond or $-C(=O)-$; ring A is a nitrogen-containing heterocycle which may be substituted; Z^1 and Z^3 are each independently a bond or a divalent chain hydrocarbon group which may be substituted; Z^2 is a bond or $-N(R^6)-$ (wherein R^6 is a hydrogen atom, a hydrocarbon group which may be substituted, or an acyl group); B is a group represented by the formula:



(wherein R^1 and R^2 are each independently a hydrogen atom, a halogen atom, a hydrocarbon group which may be substituted, an alkoxy group which may be substituted, a carboxyl group which may be esterified or amidated, an acyl group, or an amino group which may be substituted; R^3 is a hydrogen atom, a hydrocarbon group which may be

Application Number 10/574048

Response to Office Action dated 12/10/2007

substituted, a carboxyl group which may be esterified or amidated, or an acyl group; R^4 is a hydrocarbon group which may be substituted; and R^2 and R^1 or R^4 , and R^3 and R^4 may be respectively bonded to each other to form a ring which may be substituted; R^6 and R^1 , R^2 , R^3 or R^4 may be bonded to each other to form a ring which may be substituted; and a is 0, 1 or 2,

or a salt thereof.

2. (Canceled)

3. (Original) The compound according to claim 1, wherein R is an aryl group which may be substituted with a substituent selected from a halogen atom, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, amino which may be substituted, nitro, cyano, amidino which may be substituted, and carboxyl which may be esterified or amidated.

4. (Original) The compound according to claim 1, wherein R is a heterocyclic group which may be substituted with a substituent selected from a halogen atom, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, amino which may be substituted, nitro, cyano, amidino which may be substituted, and carboxyl which may be esterified or amidated.

5. (Original) The compound according to claim 1, wherein R is naphthyl which may be substituted with a halogen atom.

6. (Original) The compound according to claim 1, wherein X is a bond, X' is a bond, Y is C_{1-3} alkylene which may be substituted, and Y' is $-C(=O)-$.

7. (Original) The compound according to claim 6, wherein Y is C_{1-3} alkylene substituted with a hydroxyl group.

8. (Original) The compound according to claim 1, wherein Z^1 and Z^2 are each a bond, and Z^3 is C_{1-3} alkylene which may be substituted.

9. (Original) The compound according to claim 1, wherein ring A is a piperazine ring which may be substituted or a piperidine ring which may be substituted.

10. (Original) The compound according to claim 1, wherein ring A is a ring represented by the formula:



wherein ring A' may be further substituted,

Application Number 10/574048
 Response to Office Action dated 12/10/2007

or the formula:



wherein ring A'' may be further substituted.

11. (Original) The compound according to claim 1, wherein R⁵ is a hydrogen atom.
12. (Original) The compound according to claim 1, wherein a is 2.
13. (Currently amended) A compound selected from the group consisting of N-(4-((4-(3-((6-chloro-2-naphthyl)sulfonyl)propanoyl)-1-piperazinyl)methyl)-3-methyl-1,3-thiazol-2(3H)-ylidene)-N-methylamine, 4-((4-(3-((6-chloro-2-naphthyl)sulfonyl)propanoyl)-1-piperazinyl)methyl)-3-methyl-1,3-thiazol-2(3H)-imine, N-(5-((1-(3-((6-chloro-2-naphthyl)sulfonyl)propanoyl)-4-piperidinyl)methyl)-3-methyl-1,3-thiazol-2(3H)-ylidene)-N-methylamine, 5-(1-(3-((6-chloro-2-naphthyl)sulfonyl)propanoyl)-4-piperidinyl)-3-methyl-1,3-thiazol-2(3H)-imine, and 2-(2-((1-(3-((6-chloro-2-naphthyl)sulfonyl)propanoyl)-4-piperidinyl)imino)-1,3-thiazol-3(2H)-yl)ethanol, or a salt thereof ~~or a prodrug thereof~~.
14. (Canceled)
15. (Currently Amended) A pharmaceutical composition comprising the compound according to claim 1 ~~or 2~~.
16. (Original) The pharmaceutical composition according to claim 15, which is an anticoagulant.
17. (Original) The pharmaceutical composition according to claim 15, which is an activated blood coagulation factor X inhibitor.
18. (Currently amended) The pharmaceutical composition according to claim 15, which is a medicament for ~~preventing or treating myocardial infarction, cerebral infarction, deep vein thrombosis, pulmonary thromboembolism or atherosclerotic obliterans.~~
19. (Currently amended) The pharmaceutical composition according to claim 15, which is a medicament for preventing or treating economy-class syndrome, or treating thromboembolism during and post operation of hip replacement surgery; or the secondary onset of deep vein thrombosis.

Application Number 10/574048
Response to Office Action dated 12/10/2007

20. (Canceled)

21. (Canceled)

22. (Canceled)

23. (Canceled)

24. (Canceled)

25. (Canceled)